Application of Fmoc-amino acid carrying an unmasked carbohydrate to the synthesis of the epidermal growth factor-like domain of bovine blood coagulation factor IX by Takemura, Toshio et al.
Osaka University
Title
Application of Fmoc-amino acid carrying an unmasked
carbohydrate to the synthesis of the epidermal growth factor-
like domain of bovine blood coagulation factor IX
Author(s)Takemura, Toshio; Hojo, Hironobu; Nakahara, Yoshiaki;Ishimizu, Takeshi; Hase, Sumihiro
CitationOrganic and Biomolecular Chemistry. 2(1) P.133-P.136
Issue Date2004-01-07
Text Versionpublisher
URL http://hdl.handle.net/11094/3295
DOI
Rights
Application of Fmoc-amino acid carrying an unmasked
carbohydrate to the synthesis of the epidermal growth factor-like
domain of bovine blood coagulation factor IX†
Toshio Takemura,a Hironobu Hojo,*a Yoshiaki Nakahara,a Takeshi Ishimizu b and
Sumihiro Hase b
a Department of Applied Biochemistry, Institute of Glycotechnology, Tokai University,
Hiratsuka, Kanagawa, 259-1292, Japan
b Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Osaka,
560-0043, Japan
Received 6th October 2003, Accepted 14th November 2003
First published as an Advance Article on the web 24th November 2003
The epidermal growth factor (EGF)-like domain of the bovine blood coagulation factor IX (45–87) carrying
glucose at Ser53 was synthesized by a solid-phase method using 9-fluorenylmethoxycarbonyl (Fmoc)-amino acids.
The introduction of Ser53 was carried out using the benzotriazolyl ester of Fmoc-serine carrying an unmasked
glucose. The remaining sequence was also introduced using the benzotriazolyl ester. HPLC analysis of the crude
peptide shows that acylation of the free hydroxyl group of the glucose was not significant, demonstrating that the
amino acid carrying an unmasked carbohydrate is a useful building block for solid-phase synthesis.
Introduction
Natural proteins often retain carbohydrates, which are gener-
ally linked to the polypeptide chains via the side chain amide
bond of asparagine (N-linked glycans) or the hydroxyl groups
of serine and threonine residues (O-glycans). In the latter cases,
the reducing end sugar is usually α-linked N-acetylgalactos-
amine. In 1988 Hase et al. found a new type of O-glycosidic
linkage, Xyl-α1, 3-Xyl-α1, 3-Glc-β1-O-Ser, in the EGF-like
domains of the blood coagulation factors VII and IX.1 The
consensus sequence, which is proposed for the addition of
glucose, is C1XSXPC2 (X = any amino acid), where C1 and C2
are the first and second cysteines of the EGF-like domain. A
database search for this sequence shows that several secreted
and cell surface proteins are supposed to have this carbohydrate
modification.2 However, the role of O-glucose on the EGF
repeats remains largely unknown, except that the mutation of
the carbohydrate-linked serine residue to alanine in factor VII is
known to result in a decrease in factor VII clotting activity.3 To
understand the function of this unusual O-glycosylation from
biological and structural points of view, we synthesized the
EGF-like domain carrying glucose as shown in Fig. 1.
The synthesis of the glycopeptide has been mainly carried
out by a solid-phase method using the Fmoc protocol. The
hydroxyl groups of the carbohydrate portion are usually
protected by acetyl or benzyl groups. When acetyl-protected
amino acids are used for peptide synthesis, several prob-
lems might arise. The acetyl groups have to be removed after
the peptide chain assembly by treatment with CH3ONa
in methanol, which may cause β-elimination of serine-linked
Fig. 1 Amino acid sequence of the EGF-like domain of the bovine
blood coagulation factor IX (45–87).
† Electronic supplementary information (ESI) available: experimental
details. See http://www.rsc.org/suppdata/ob/b3/b312413d/
carbohydrates and epimerization of amino acid residues. In
addition, the acetyl group tends to migrate to the terminal
amino group of the growing peptide chain during solid-phase
synthesis, which prevents further elongation of the peptide
chain. In the case of the benzyl group, no such problems arise,
as its removal can be achieved either by catalytic hydrogenation
or mild acid treatment, and also the benzyl group does not
migrate under the conditions used for solid-phase synthesis.
However, for the synthesis of the EGF-like domain carrying
β-linked glucose, the use of benzyl protection would be
inconvenient, since the glycosylation of Fmoc-serine by benzyl-
protected glucose may not yield the desired β-anomer as a
major product.
Recently, several reports appeared on the use of Fmoc-amino
acids carrying unprotected carbohydrates for the solid phase
synthesis of glycopeptide.4–11 In particular, Yamamoto et al.
prepared Fmoc-Asn carrying an oligosaccharide with free
hydroxyl groups from eggs and used it for the glycopeptide syn-
thesis.11 This method will open a facile route to N-glycopeptides
without laborious chemical synthesis of the carbohydrate
moiety. However, when unmasked derivatives are used for the
solid-phase synthesis, there is a potential risk of O-acylation on
the free hydroxyl groups of the carbohydrate moiety. In pre-
vious reports, mild coupling methods, such as pentafluoro-
phenyl or benzotriazolyl esters, are employed to avoid this
issue. At present the application of amino acids carrying
unmasked carbohydrates for glycopeptide synthesis is limited to
relatively short peptides (less than 20 amino acid residues) and
thus, its practical use for longer peptides has to be clarified. In
this report, we synthesized Fmoc-serine carrying unprotected
β-glucose and applied it to the synthesis of the EGF-like
domain of the bovine blood coagulation factor IX (45–87).
There are many reports on the synthesis of the EGF-like
domain of proteins,12–24 but the chemical synthesis of the
glycosylated EGF-like domain has not appeared so far.
Results and discussion
Synthesis of the EGF-like domain
Fmoc-Ser(Glc) 7 was prepared as shown in Fig. 2. The Fmoc-
serine allyl ester was glycosylated with tetraacetyl glucosyl
bromide 3 using silver triflate as an activator to give compoundD
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4. During the glycosylation reaction, a part of the hydroxyl
group of the Fmoc-serine allyl ester was acetylated, which
decreased the yield of the desired product. This side product
might be derived from the orthoester. The purified yield of the
desired product 4 was 34%. The allyl group was removed by a
Pd(0) catalyst in the presence of N-methylaniline (NMA), and
compound 5 was obtained quantitatively. The Fmoc and acetyl
groups were simultaneously removed by CH3ONa in methanol.
Without purification, the obtained product 6 was reacted with
N-(9-fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu).
The desired building block 7 was obtained after RPHPLC
purification in 68% yield from compound 5.
The solid-phase synthesis of the EGF-like domain was
carried out as shown in Fig. 3. Starting from Fmoc-Thr(But)-
OCH2-PEG-PS resin, the peptide chain was elongated using
an ABI 433A peptide synthesizer employing the FastMoc
protocol. After the introduction of Asn54, a part of the resin
was taken and the chain elongation was continued manually.
The Fmoc group of the resin was removed by 20% piperidine–
NMP and the Fmoc-Ser(Glc) 7 was introduced manually
using its benzotriazolyl ester (3 eq.). The reaction mixture was
vortexed at room temperature for 30 min and at 50 C for
15 min. Ninhydrin monitoring indicated the completion of the
coupling. The remaining sequence was also introduced manu-
ally using the benzotriazolyl ester (20 eq.) in the same manner.
After complete assembly of the peptide sequence, the resin was
treated with a trifluoroacetic acid (TFA) cocktail (Reagent K 25)
Fig. 2 Synthetic procedure for Fmoc-Ser carrying unmasked glucose.
a) Fmoc-Ser-OAll, AgOTf; b) Pd(PPh3)4, NMA; c) CH3ONa–MeOH;
d) Fmoc-OSu.
Fig. 3 Synthetic route for the EGF-like domain of bovine factor IX 1.
and the crude peptide was analyzed by RPHPLC. Since the
peptide is in reduced form, which is free from the disulfide
bond isomer, precise detection of the O-aclyation product
would be expected. However, as shown in Fig. 4a, the peptide
with six thiol groups was strongly adsorbed to the RPHPLC
column at 30 C. Though the adsorption became weaker as
the column temperature increased from 30 C to 60 C, com-
plete elution was not possible. Thus, the purity of the crude
peptide was not estimated at this stage. The folding and the
disulfide bond formation were then carried out using the
redox buffer containing reduced and oxidized glutathione at
pH 8.0. After 3 days, the same amount of crude peptide was
analyzed by RPHPLC. As shown in Figs 4c and d, a sharp
peak, which has the desired mass number, was obtained as a
major product regardless of the column temperature. Mass
analysis of smaller peaks eluted after the major peak in Fig. 4c
showed that these peaks mainly consist of the disulfide bond
isomers. The main peak was purified by preparative RPHPLC
and the desired EGF-like domain carrying glucose was
obtained in 3.4% yield. To estimate the efficiency of this syn-
thesis, non-glycosylated EGF-like domain 2 was prepared
totally by the synthesizer using the FastMoc protocol, which
uses O-benzotriazol-1-yl-N,N,N,N-tetramethyluronium hexa-
fluorophosphate (HBTU) as a coupling reagent. As shown in
Figs 4e and f, the RPHPLC profile of this peptide is similar to
that of glycosylated EGF-like domain 1. The yield of the puri-
fied non-glycosylated EGF-like domain 2 was 3.7%, which is
comparable to the glycosylated peptide 1. Thus, the syntheses
of two EGF-like domains proceeded with comparable effi-
ciency, which means that the acylation of the free hydroxy
groups of the carbohydrate portion is not significant. The puri-
fied peptides 1 and 2 were homogeneous, which was shown by
Fig. 4 RPHPLC profiles of the crude glycosylated peptide 1 and non-
glycosylated peptide 2: a) and b); peptide 1 before oxidation (ca. 90 µg
of crude peptide), c) and d); peptide 1 after oxidation (ca. 90 µg of
crude peptide), e) and f ); peptide 2 after oxidation (ca. 80 µg of crude
peptide). Elution conditions: column, Mightysil RP-18GP (4.6 ×
150 mm) at a flow rate of 1 ml min1; eluent A, distilled water
containing 0.1% TFA, B, acetonitrile containing 0.1% TFA.
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Table 1 MALDI-TOF mass analysis of the peptide fragments obtained after thermolytic digestion of peptides 1 and 2
 Fragments Expected (M  H) From peptide 1 observed (M  H) From peptide 2 observed (M  H)
A 1244.4 — 1244.1
B 899.3 899.6 899.2
C 2011.8 2011.9 a —
a This data was obtained by the BrCN treatment followed by the Staphylococcus aureus protease V8 digestion of peptide 1. 
MALDI-TOF mass spectrometry, RPHPLC (Fig. 5) and by
amino acid analyses.
Determination of the disulfide pairings
To determine the mode of disulfide linkages, the synthetic pep-
tides were digested with thermolysin at 45 C for 24 h and the
peptide fragments were separated by RPHPLC. Each fraction
was analyzed by the mass and amino acid analyses. In the case
of the non-glycosylated peptide 2, peptide fragments A and B
were obtained (Table 1), which correspond to the correct
disulfide bond shown in Fig. 1. In contrast, glycosylated
peptide 1 seemed to be somewhat more resistant to the
digestion by thermolysin. Even after 24 h digestion, the peptide
bond between Cys51-Glu52 was not cleaved. To determine the
N-terminal disulfide pairings, peptide 1 was treated with BrCN
to cleave Met61-Cys62 and was further digested with Staphylo-
coccus aureus protease V8. The digest was analyzed by
RPHPLC and fragment C was obtained, which shows the
formation of the disulfide bond between Cys51-Cys62. The
C-terminal disulfide bond was determined by the thermolysin
digestion for 24 h as described above.
In conclusion, Fmoc-serine carrying an unmasked glucose was
prepared by the solution method. This unit was successfully
used during the solid-phase synthesis of the EGF-like domain
of bovine Factor IX by the benzotriazolyl active ester method,
indicating that the glycopeptides can be synthesized without
hydroxyl group protection at the carbohydrate moiety, if mild
activation methods are employed.
Experimental
Optical rotation values were determined with a DIP-370 polar-
imeter (Jasco, Tokyo) at 20 C ± 5 C. 1H-NMR spectra were
recorded with a AL-400 spectrometer (Jeol, Tokyo). MALDI-
TOF mass spectra were recorded with a Voyager-DE PRO spec-
trometer (Applied Biosystems, CA). Amino acid composition
was determined with a LaChrom amino acid analyzer (Hitachi,
Tokyo) after hydrolysis with 6 M HCl at 150 C for 2 h in an
evacuated sealed tube.
Fig. 5 RPHPLC profile of the purified peptide 1 (a) and 2 (b). Elution
conditions: column, Mightysil RP-18GP (4.6 × 150 mm) at a flow rate
of 1 ml min1; eluent A, distilled water containing 0.1% TFA, B,
acetonitrile containing 0.1% TFA; temperature, 30 C.
N-(9-Fluorenylmethoxycarbonyl)-O-(-D-glucopyranosyl)-L-
serine 7
To the solution of compound 5 (500 mg, 760 µmol) in methanol
(2 ml), 1 M CH3ONa solution in methanol (1.0 ml, 1.0 mmol)
was added and the reaction mixture was stirred at room tem-
perature for 3 h. The solution was neutralized by 1 M HCl and
the solvent was removed in vacuo. The residue was dissolved in
distilled water and washed with ether (×3) and lyophilized to
give compound 6. The obtained powder was dissolved in 10%
Na2CO3 (5 ml) and was dropped into the solution of Fmoc-
OSu (385 mg, 1.1 mmol) in dimethoxyethane (5 ml). After the
reaction mixture was kept at room temperature overnight, the
solution was washed with ether (×3) and acidified by 1 M HCl.
The product was extracted by 1-butanol and purified by
RPHPLC to give compound 7 (250 mg, 510 µmol, 68%). Rf
0.58 (4 : 1 : 1 1-butanol–AcOH—H2O); [α]D 4.0 (c 0.9 in
methanol); Anal. calcd for C24H27NO101/2 H2O: C, 57.83; H,
5.66; N, 2.81. Found: C, 57.62; H, 5.47; N, 3.07; 1H NMR
(CD3SOCD3): δ 7.90 (d, 2H, J 7.6 Hz, Ar), 7.76–7.73 (m, 2H,
Ar), 7.70 (d, 1H, J 9.0, NH) 7.43 (br t, 2H, J 7.4 Hz, Ar), 7.34
(br t, 2H, J 7.4 Hz, Ar), 4.15 (d, 1H, J 7.6 Hz, H-1), 3.68 (br d,
1H, J 10.7 Hz, H-6), 3.62 (dd, 1H, J 3.3 Hz, 9.9 Hz, Ser-βH),
3.44 (dd, 1H, J 5.7 Hz, 11.8 Hz, H-6), 3.16 (br t, 1H, J 8.8 Hz,
H-3), 3.05 (t, 1H, J 9.0 Hz, H-4), 2.98 (t, 1H, J 8.3 Hz, H-2);
MALDI-TOF MS: calcd for C24H25NO10Na m/z 512.15. Found
m/z 512.07.
Solid-phase synthesis of the glycosylated EGF-like domain
(45–57) 1
Starting from Fmoc-Thr(But)-OCH2-PEG-PS resin (0.25 mmol
g1, 0.4 g), the peptide chain was elongated by an ABI 433A
peptide synthesizer (Applied Biosystems, Foster City) employ-
ing FastMoc protocol. After Fmoc-Asn(Trt)-Pro-Cys(Trt)-
Leu-Asn(Trt)-Gly-Gly-Met-Cys(Trt)-Lys(Boc)-Asp(OBut)-
Asp(OBut)-Ile-Asn(Trt)-Ser(But)-Tyr(But)-Glu(OBut)-
Cys(Trt)-Trp(Boc)-Cys(Trt)-Gln(Trt)-Ala-Gly-Phe-Glu(OBut)-
Gly-Thr(But)-Asn(Trt)-Cys(Trt)-Glu(OBut)-Leu-Asp(OBut)-
Ala-Thr(But)-OCH2-PEG-PS-Resin was obtained, a part of
this resin (6.3 µmol) was taken and the Fmoc group was
removed with 20% piperidine-1-methyl-2-pyrrolidinone (NMP)
for 5 and 15 min. Fmoc-Ser(Glc) 7 (9.2 mg, 19 µmol) was pre-
activated with 1 M 1,3-dicyclohexylcarbodiimide (DCC)–NMP
(23 µl) and 1 M 1-hydroxybenzotriazole (HOBt)–NMP (23 µl)
for 30 min at room temperature and reacted with the resin at
room temperature for 30 min. The reaction mixture was further
vortexed at 50 C for 15 min. A ninhydrin test indicated the
complete introduction of the glucosyl serine residue. The
remaining sequence was introduced manually using Fmoc-
amino acid benzotriazolyl ester (130 µmol). After complete
assembly of the peptide sequence, the Fmoc group was
removed and the resin was dried in vacuo. A part of the resin
(50 mg out of 68 mg obtained) was treated with Reagent K
(500 µl) for 2 h at room temperature. TFA was removed by a
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nitrogen stream and the ether was added to form a pre-
cipitate, which was washed twice with ether and dried in vacuo.
The peptide was extracted by 50% aqueous acetonitrile
containing 0.1% TFA (2 ml) and filtered through a membrane
filter. The solution was dropped into 0.1 M ammonium
acetate (50 ml, pH 8.0) containing oxidized (3 mg) and reduced
forms of glutathione (15 mg) and was stirred for 3 days at
room temperature. The solution was acidified by acetic acid
and loaded onto a RPHPLC column. The main fraction was
collected and lyophilized to give the desired peptide 1. The
yield was 160 nmol (3.4% based on the Thr content on the
starting resin) MADLI-TOF MS found: m/z 4853.7 (M  H).
Calcd: m/z 4853.8 (M  H); amino acid analysis; Asp9.13-
Thr1.85Ser1.66Glu5.88Pro0.86Gly5Ala2.04Cys0.99 Val0.97Met0.94 Ile1.00-
Leu2.08Tyr2.00Phe1.01Lys1.00.
The determination of the disulfide bridge of the EGF-like domain
EGF-like domain 1 or 2 (100 µg) was dissolved in 0.1 M
pyridine acetate (pH 6.5, 100 µl) and 20 µg of thermolysin
was added. The solution was kept at 45 C for 24 h. The
peptide fragment was separated by RPHPLC and analyzed by
MALDI-TOF mass and amino acid analyzer. In the case of
peptide 1, the peptide (100 µg) was dissolved in 70% formic acid
and treated with BrCN (100 µg, 1.0 µmol) for 24 h at room
temperature in the dark. The solvent was removed in vacuo and
the residual mass was dissolved in distilled water and lyophil-
ized. The obtained powder was dissolved in 0.1 M NH4HCO3
(40 µl) and digested with Staphylococcus aureus protease V8 (20
µg) at 40 C for 3 h and purified by RPHPLC. Each fraction was
analyzed by MADLI-TOF MS.
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